Neurol. praxi. 2018;19(6):436-439 | DOI: 10.36290/neu.2018.151

Teriflunomide in young women

MUDr. Petra Praksová, Ph.D.
Neurologie Lidická s.r.o., Neurologická klinika LF MU FN Brno

Teriflunomide is medicine used for treatment of relapsing- remitting multiple sclerosis. It is administered as oral tablet once daily.Its safety profile and effectiveness were verified in four clinical trials and is supported with 13 years of clinical experience. Medicineis well tolerated by patients, adverse effects are mostly mild to moderate. This article shows on important data for clinical practiceespecially focused on treatment of young women, that are necessary to consider before and during treatment with teriflunomide.

Keywords: multiple sclerosis, teriflunomide, young women, pregnancy, accelerated elimination

Received: February 28, 2019; Accepted: May 9, 2019; Prepublished online: May 9, 2019; Published: December 10, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Praksová P. Teriflunomide in young women. Neurol. praxi. 2018;19(6):436-439. doi: 10.36290/neu.2018.151.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014; 74(6): 659-674. Go to original source...
    2. Cahill JF, Izzo A, Garg N. Immunization in patients with multiple sclerosis. Neurological Bulletin 2010; 2: 17-21. Go to original source...
    3. Comi G, Freedman MS, Kappos L, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord 2016; 5: 97-104. Go to original source... Go to PubMed...
    4. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar; 13(3): 247-256. Go to original source...
    5. Davenport L, Czich A, Turpault S. Teriflunomide: no effects on sperm DNA. Mult. Scler. J. 2013; 19: P1187.
    6. EMA approval of Aubagio, dostupné na: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002514/WC500144913.pdf.
    7. Chan A, de Seze J, Comabella M. Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis. CNS Drugs. 2016; 30: 41-51. Go to original source... Go to PubMed...
    8. Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014 Nov 20; 3(2): 133-138. Go to original source...
    9. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW. TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Oct; 13(10): 977-986. Go to original source...
    10. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP., Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS for the TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303. Go to original source...
    11. Queisser-Luft A, Stolz G, Wiesel A, Schlaefer K, Spranger J. Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990-1998). Arch Gynecol Obstet. 2002 Jul; 266(3): 163-167. Go to original source...
    12. Souhrn údajů o přípravku Arava, dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000235/WC500026289.pdf
    13. Souhrn údajů o přípravku Aubagio, dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf.
    14. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. International MS Journal/MS Forum. 2008; 15(2): 62-68. Go to PubMed...
    15. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014; 20(6): 705-716. Go to original source... Go to PubMed...
    16. Vukusic S. Pregnancy outcomes in patients with MS treated with teriflunomide: clinical study and post-marketing data. ECTRIMS 2017. Oct 27; oral presentation 205.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.